RT002 - Injectable Botulinum Toxin Type A
Revance is developing a next generation injectable product (RT002) integrating the TransMTS™ technology. RT002 is an investigational product in pre-clinical development.
Pre-Clinical Promise
In preclinical testing, RT002 has improved duration of action with less spread than injectable botulinum toxin type A1.
Opportunity to Improve Current Treatment
While worldwide the botulinum toxin type A market is large and growing - with 2.5 million injections in 2008, significant growth since the approval of Botox® Cosmetic in 2002 (source: 2008 ASAPS annual statistics); there is always the desire from both physicians and patients to improve performance by increasing duration of the treatment or speeding the onset of action. Additionally, the recent FDA mandate for a boxed warning and implementation of a Risk Evaluation and Mitigation Strategy (REMS) for currently marketed botulinum toxins emphasizes the need for a product with lower risk of diffusion away from the treatment site.
Revance's TransMTS technology, integrated with an injectable toxin, could improve onset of action, increase duration of effect, and limit diffusion away from treatment site. The RT002 program aims to address market needs and improve performance compared to the currently available treatments.
BOTOX® is a registered trademark of Allergan, Incorporated; DYSPORT® is a registered trademark of Ipsen
1Data on file